Symbols / ATHA
ATHA Chart
About
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 26.62M |
| Enterprise Value | 1.52M | Income | -37.72M | Sales | — |
| Book/sh | 6.79 | Cash/sh | 6.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 26 | IPO | Sep 18, 2020 |
| P/E | — | Forward P/E | -4.14 | PEG | — |
| P/S | — | P/B | 0.99 | P/C | — |
| EV/EBITDA | -0.04 | EV/Sales | — | Quick Ratio | 9.05 |
| Current Ratio | 9.70 | Debt/Eq | 3.40 | LT Debt/Eq | — |
| EPS (ttm) | -9.67 | EPS next Y | -1.63 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -42.21% |
| ROE | -89.42% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.94M |
| Shs Float | 981.20K | Short Float | 0.21% | Short Ratio | 0.37 |
| Short Interest | — | 52W High | 8.36 | 52W Low | 2.20 |
| Beta | 2.80 | Avg Volume | 1.07M | Volume | 70.31K |
| Target Price | $4.00 | Recom | None | Prev Close | $7.19 |
| Price | $6.75 | Change | -6.12% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$6.75
Latest analyst target
3. DCF / Fair value
$-138.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.75
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-09-19 | down | Mizuho | Outperform → Neutral | $1 |
| 2024-09-04 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2024-09-04 | down | BTIG | Buy → Neutral | — |
| 2024-08-19 | init | Rodman & Renshaw | — → Buy | $22 |
| 2024-06-20 | reit | JMP Securities | Market Outperform → Market Outperform | $19 |
| 2024-05-16 | reit | JMP Securities | Market Outperform → Market Outperform | $19 |
| 2023-08-11 | main | JMP Securities | Outperform → Outperform | $19 |
| 2023-05-15 | main | Mizuho | Buy → Buy | $5 |
| 2023-03-30 | main | BTIG | — → Buy | $10 |
| 2023-03-24 | reit | JMP Securities | — → Market Outperform | $20 |
| 2022-07-07 | init | Mizuho | — → Buy | $6 |
| 2022-06-23 | down | Stifel | Buy → Hold | $5 |
| 2022-06-23 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2022-06-23 | down | Jefferies | Buy → Hold | $3 |
| 2022-05-10 | init | BTIG | — → Buy | $33 |
| 2022-04-21 | init | Berenberg | — → Buy | $33 |
| 2021-12-15 | init | Goldman Sachs | — → Neutral | $16 |
| 2020-10-13 | init | Jefferies | — → Buy | $30 |
| 2020-10-13 | init | JMP Securities | — → Market Outperform | — |
| 2020-10-13 | init | Stifel | — → Buy | $36 |
- Why Atha Energy Stock Is Quietly Powering Higher - TipRanks ue, 24 Feb 2026 17
- New breast cancer drug moves into late testing with $236M funding deal - Stock Titan hu, 18 Dec 2025 08
- Athira Pharma Announces Reverse Stock Split - GlobeNewswire hu, 11 Sep 2025 07
- Worthington, Athira Pharma general counsel, sells $6k in ATHA stock - Investing.com Mon, 05 Jan 2026 08
- Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? - Stocktwits hu, 18 Dec 2025 08
- Athira Pharma Announces 10-for-1 Reverse Stock Split - Nasdaq hu, 11 Sep 2025 07
- Athira Pharma Inc.: Growth or Bubble? - StocksToTrade hu, 18 Dec 2025 08
- Why Is Athira Pharma Stock (ATHA) Up Today? - TipRanks hu, 18 Dec 2025 08
- Athira Pharma CSO Church sells $6k in ATHA stock - Investing.com Mon, 05 Jan 2026 08
- Insider Sale: CHIEF MEDICAL OFFICER of $ATHA Sells 1,644 Shares - Quiver Quantitative ue, 06 Jan 2026 08
- Uranium explorer ATHA pours C$63M into Nunavut drilling push - Stock Titan Mon, 09 Feb 2026 08
- Uranium explorer raises C$63M to drill remote Nunavut project - Stock Titan hu, 05 Feb 2026 08
- Why Atha Energy Stock Is Quietly Climbing Higher - TipRanks hu, 22 Jan 2026 08
- Biotech behind new breast cancer trial takes on a new name - Stock Titan Fri, 09 Jan 2026 08
- Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug - Investing.com hu, 18 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2586 | 17792.0 | — | Sale at price 6.88 per share. | LITTON MARK JAMES | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 1644 | 11311.0 | — | Sale at price 6.88 per share. | SAN MARTIN JAVIER | Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 876 | 6027.0 | — | Sale at price 6.88 per share. | CHURCH KEVIN | Officer | — | 2026-01-02 00:00:00 | D |
| 3 | 876 | 6027.0 | — | Sale at price 6.88 per share. | WORTHINGTON MARK | General Counsel | — | 2026-01-02 00:00:00 | D |
| 4 | 297 | 2043.0 | — | Sale at price 6.88 per share. | RENNINGER ROBERT | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 5 | 10834 | nan | — | — | LITTON MARK JAMES | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 6 | 4667 | nan | — | — | SAN MARTIN JAVIER | Officer | — | 2025-12-31 00:00:00 | D |
| 7 | 3667 | nan | — | — | CHURCH KEVIN | Officer | — | 2025-12-31 00:00:00 | D |
| 8 | 3667 | nan | — | — | WORTHINGTON MARK | General Counsel | — | 2025-12-31 00:00:00 | D |
| 9 | 1236 | nan | — | — | RENNINGER ROBERT | Chief Financial Officer | — | 2025-12-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -91.68M | -127.60M | -78.01M | -54.71M |
| TotalUnusualItems | -4.13M | 1.63M | -10.00M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -4.13M | 1.63M | -10.00M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -96.94M | -117.67M | -95.64M | -54.85M |
| ReconciledDepreciation | 970.00K | 969.00K | 845.00K | 479.00K |
| EBITDA | -95.81M | -125.97M | -88.01M | -54.71M |
| EBIT | -96.78M | -126.94M | -88.86M | -55.19M |
| NetInterestIncome | 334.00K | |||
| InterestExpense | 3.00K | |||
| InterestIncome | 337.00K | |||
| NormalizedIncome | -92.81M | -119.30M | -85.64M | -54.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -96.94M | -117.67M | -95.64M | -54.85M |
| TotalExpenses | 96.78M | 126.94M | 88.86M | 55.19M |
| TotalOperatingIncomeAsReported | -100.90M | -125.47M | -104.02M | -64.02M |
| DilutedAverageShares | 3.85M | 3.80M | 3.77M | 3.69M |
| BasicAverageShares | 3.85M | 3.80M | 3.77M | 3.69M |
| DilutedEPS | -25.20 | -30.90 | -25.30 | -14.90 |
| BasicEPS | -25.20 | -30.90 | -25.30 | -14.90 |
| DilutedNIAvailtoComStockholders | -96.94M | -117.67M | -95.64M | -55.27M |
| NetIncomeCommonStockholders | -96.94M | -117.67M | -95.64M | -55.27M |
| OtherunderPreferredStockDividend | 1.57M | 421.00K | ||
| NetIncome | -96.94M | -117.67M | -95.64M | -54.85M |
| NetIncomeIncludingNoncontrollingInterests | -96.94M | -117.67M | -95.64M | -54.85M |
| NetIncomeContinuousOperations | -96.94M | -117.67M | -95.64M | -54.85M |
| PretaxIncome | -96.94M | -117.67M | -95.64M | -54.85M |
| OtherIncomeExpense | -165.00K | 9.27M | -6.78M | 334.00K |
| OtherNonOperatingIncomeExpenses | 3.96M | 7.64M | 3.22M | 334.00K |
| SpecialIncomeCharges | -4.13M | 1.63M | -10.00M | 0.00 |
| OtherSpecialCharges | 4.13M | -1.63M | 10.00M | |
| NetNonOperatingInterestIncomeExpense | 334.00K | |||
| InterestExpenseNonOperating | 3.00K | |||
| InterestIncomeNonOperating | 337.00K | |||
| OperatingIncome | -96.78M | -126.94M | -88.86M | -55.19M |
| OperatingExpense | 96.78M | 126.94M | 88.86M | 55.19M |
| OtherOperatingExpenses | -157.00K | -5.16M | -8.84M | |
| ResearchAndDevelopment | 70.68M | 93.79M | 61.46M | 42.79M |
| SellingGeneralAndAdministration | 26.09M | 33.30M | 32.55M | 21.23M |
| GeneralAndAdministrativeExpense | 26.09M | 33.30M | 32.55M | 21.23M |
| OtherGandA | 26.09M | 33.30M | 32.55M | 21.23M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 3.90M | 3.82M | 3.79M | 3.74M |
| ShareIssued | 3.90M | 3.82M | 3.79M | 3.74M |
| TotalDebt | 1.22M | 1.58M | 1.91M | 1.92M |
| TangibleBookValue | 44.84M | 130.19M | 235.14M | 321.08M |
| InvestedCapital | 44.84M | 130.19M | 235.14M | 321.08M |
| WorkingCapital | 41.71M | 125.89M | 186.10M | 251.51M |
| NetTangibleAssets | 44.84M | 130.19M | 235.14M | 321.08M |
| CapitalLeaseObligations | 1.22M | 1.58M | 1.91M | 1.92M |
| CommonStockEquity | 44.84M | 130.19M | 235.14M | 321.08M |
| TotalCapitalization | 44.84M | 130.19M | 235.14M | 321.08M |
| TotalEquityGrossMinorityInterest | 44.84M | 130.19M | 235.14M | 321.08M |
| StockholdersEquity | 44.84M | 130.19M | 235.14M | 321.08M |
| GainsLossesNotAffectingRetainedEarnings | 1.00K | -349.00K | -1.96M | -388.00K |
| OtherEquityAdjustments | 1.00K | -349.00K | -1.96M | |
| RetainedEarnings | -406.15M | -309.21M | -191.53M | -95.89M |
| AdditionalPaidInCapital | 450.98M | 439.74M | 428.62M | 417.36M |
| CapitalStock | 4.00K | 4.00K | 4.00K | 4.00K |
| CommonStock | 4.00K | 4.00K | 4.00K | 4.00K |
| TotalLiabilitiesNetMinorityInterest | 13.94M | 30.06M | 23.02M | 10.92M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 803.00K | 1.22M | 1.58M | 1.63M |
| LongTermDebtAndCapitalLeaseObligation | 803.00K | 1.22M | 1.58M | 1.63M |
| LongTermCapitalLeaseObligation | 803.00K | 1.22M | 1.58M | 1.63M |
| CurrentLiabilities | 13.13M | 28.84M | 21.43M | 9.29M |
| CurrentDebtAndCapitalLeaseObligation | 414.00K | 368.00K | 326.00K | 288.00K |
| CurrentCapitalLeaseObligation | 414.00K | 368.00K | 326.00K | 288.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.99M | 4.54M | 3.42M | 1.91M |
| PayablesAndAccruedExpenses | 9.73M | 23.93M | 17.69M | 7.10M |
| CurrentAccruedExpenses | 9.41M | 23.80M | 15.19M | 6.53M |
| Payables | 319.00K | 129.00K | 2.50M | 567.00K |
| AccountsPayable | 319.00K | 129.00K | 2.50M | 567.00K |
| TotalAssets | 58.78M | 160.25M | 258.15M | 332.01M |
| TotalNonCurrentAssets | 3.94M | 5.52M | 50.62M | 71.21M |
| OtherNonCurrentAssets | 686.00K | 1.08M | 475.00K | 56.00K |
| InvestmentsAndAdvances | 0.00 | 44.83M | 65.94M | |
| InvestmentinFinancialAssets | 0.00 | 44.83M | 65.94M | |
| NetPPE | 3.25M | 4.44M | 5.32M | 5.22M |
| AccumulatedDepreciation | -3.29M | -2.33M | -1.37M | -523.00K |
| GrossPPE | 6.55M | 6.77M | 6.68M | 5.74M |
| Leases | 4.32M | 4.32M | 4.30M | 2.56M |
| ConstructionInProgress | 0.00 | 1.12M | ||
| OtherProperties | 1.51M | 1.74M | 1.70M | 1.73M |
| MachineryFurnitureEquipment | 712.00K | 712.00K | 692.00K | 325.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 54.84M | 154.73M | 207.53M | 260.80M |
| OtherCurrentAssets | 3.57M | 5.68M | 5.96M | 4.70M |
| PrepaidAssets | 4.70M | |||
| Receivables | 0.00 | 1.63M | 1.23M | 2.34M |
| OtherReceivables | 1.63M | 1.23M | 2.34M | |
| CashCashEquivalentsAndShortTermInvestments | 51.27M | 147.42M | 200.34M | 253.76M |
| OtherShortTermInvestments | 2.84M | 56.84M | 104.38M | 143.22M |
| CashAndCashEquivalents | 48.44M | 90.58M | 95.97M | 110.54M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -97.20M | -101.06M | -73.61M | -44.67M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 96.76M | ||
| CapitalExpenditure | -33.00K | -304.00K | -1.14M | -1.57M |
| EndCashPosition | 49.07M | 91.22M | 96.39M | 110.54M |
| BeginningCashPosition | 91.22M | 96.39M | 110.54M | 60.62M |
| ChangesInCash | -42.15M | -5.17M | -14.15M | 49.91M |
| FinancingCashFlow | 194.00K | 493.00K | 654.00K | 97.09M |
| CashFlowFromContinuingFinancingActivities | 194.00K | 493.00K | 654.00K | 97.09M |
| ProceedsFromStockOptionExercised | 194.00K | 493.00K | 654.00K | 327.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 96.76M | ||
| CommonStockIssuance | 0.00 | 96.76M | ||
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 54.83M | 95.09M | 57.66M | -4.08M |
| CashFlowFromContinuingInvestingActivities | 54.83M | 95.09M | 57.66M | -4.08M |
| NetInvestmentPurchaseAndSale | 54.86M | 95.39M | 58.80M | -2.51M |
| SaleOfInvestment | 69.00M | 123.06M | 154.09M | 296.69M |
| PurchaseOfInvestment | -14.13M | -27.67M | -95.29M | -299.20M |
| NetPPEPurchaseAndSale | -33.00K | -304.00K | -1.14M | -1.57M |
| PurchaseOfPPE | -33.00K | -304.00K | -1.14M | -1.57M |
| OperatingCashFlow | -97.17M | -100.75M | -72.47M | -43.10M |
| CashFlowFromContinuingOperatingActivities | -97.17M | -100.75M | -72.47M | -43.10M |
| ChangeInWorkingCapital | -11.98M | 6.53M | 11.94M | 6.00M |
| ChangeInOtherCurrentLiabilities | -368.00K | -326.00K | -15.00K | 241.00K |
| ChangeInPayablesAndAccruedExpense | -15.75M | 7.37M | 12.10M | 5.15M |
| ChangeInAccruedExpense | -10.00M | 0.00 | 10.00M | 0.00 |
| ChangeInPayable | -5.75M | 7.37M | 2.10M | 5.15M |
| ChangeInAccountPayable | -5.75M | 7.37M | 2.10M | 5.15M |
| ChangeInPrepaidAssets | 2.51M | -113.00K | -1.26M | 1.65M |
| ChangeInReceivables | 1.63M | -401.00K | 1.11M | -1.04M |
| OtherNonCashItems | 241.00K | 214.00K | 203.00K | 155.00K |
| StockBasedCompensation | 11.05M | 10.62M | 10.61M | 4.62M |
| AmortizationOfSecurities | -515.00K | -1.41M | -422.00K | 493.00K |
| DepreciationAmortizationDepletion | 970.00K | 969.00K | 845.00K | 479.00K |
| DepreciationAndAmortization | 970.00K | 969.00K | 845.00K | 479.00K |
| Depreciation | 970.00K | 969.00K | 845.00K | 479.00K |
| OperatingGainsLosses | 7.00K | |||
| GainLossOnSaleOfPPE | 7.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -96.94M | -117.67M | -95.64M | -54.85M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ATHA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|